M Pharmaceutical, Specializing in Obesity and Diabetes Technologies, Appoints Douglas Janzen as Senior Clinical Advisor - Video News Alert on InvestmentPitch.com

May 20, 2015 10:47 AM EDT | Source: InvestmentPitch Media

Vancouver, British Columbia--(Newsfile Corp. - May 20, 2015) - M Pharmaceutical (CSE: MQ) which specializes in developing and commercializing innovative biomedical technologies that improve the health and quality of life for people affected by obesity and diabetes, has appointed Douglas Janzen as Senior Clinical Advisor to the company.

Mr. Janzen, an established leader in the life sciences and biotechnology sectors with more than 20 years of leadership experience in corporate finance, business development and management, is the Co-Founder and Managing Director of Northview Ventures, and President and CEO of Aequus Pharmaceuticals, and sits on the boards of several life sciences and biotechnology companies.

InvestmentPitch.com has produced a "video news alert" which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter "M Pharma" in the search box. While on the site please view Dr. Mintchev's interview and corporate presentation.


If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_r3n28rp7/M-Pharmaceutical-CSE-MQ-Appoints-Douglas-Janzen-as-Senior-Clinical-Advisor

Dr. Martin Mintchev, President and CEO, stated: "We are, of course, very pleased to have someone of Douglas's stature and background join us as Senior Clinical Advisor. With his leadership reputation in biotechnology, pharma and life sciences and an impressive toolkit in the areas of entrepreneurship, finance and business development, Douglas is bound to deliver significant added value to everything we do in bringing our own innovative biomedical technologies to market."

Before founding Northview Ventures, a strategic investment and consulting firm focused on life sciences and high tech, Janzen served nine years as a senior executive at Cardiome Pharma, holding various leadership positions, where he raised more than $300 million and completed over $1 billion in licensing deals.

Prior to Cardiome, Janzen was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences. He has completed more than $1 billion in equity financing for Canadian bio-tech companies and has previously served as chair of LifeSciences BC and as a director with Biotech Canada.

Janzen is also a former winner of Business in Vancouver's "Top 40 Under 40 Award".

This follows the recent announcement that Dr. Christopher Andrews, M.D., MSc, FRCPC, a highly-respected Gastroenterologist, faculty member of the Department of Medicine at the University of Calgary and graduate of the Mayo Clinic in Rochester, MN, joined the Board of Directors of M Pharmaceutical Inc.

M Pharma currently has the exclusive rights to a family of biomedical technologies including (i) the eMosquito, for automatic and autonomous monitoring of blood glucose in diabetics; (ii) temporary controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss that has been recently tested in blind, placebo-controlled human studies; and (iii) gastrointestinal neurostimulators, using a laparoscopically-implantable technique for the treatment of obesity without permanent anatomical modification of the stomach.

Commercial development of these technologies will require successful coordination and execution of a wide variety of technology disciplines.

The company is trading at $0.20 and with 14.3 million shares outstanding, is capitalized at $2.9 million.

For more information, please visit the company's website www.m-pharma.ca, call 604-428-0511 or email info@m-pharma.ca.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing short three minute videos based on significant news releases and research reports.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com

info